

Aurigene Pharmaceutical Services Limited (APSL) invests in adding Large Molecule Discovery and Development Services

The new offering will support clients with discovery and development services for New Biological Entities (NBE)

Hyderabad, India, November, 11, 2021

Aurigene Pharmaceutical Services Limited, a wholly-owned subsidiary of Dr. Reddy's expands its existing discovery and development capacities with the inauguration of a biotherapeutics discovery facility in Hyderabad, India. Named New Biological Entity (NBE) Services, this division will complement Aurigene Pharmaceutical Services' offerings to global biopharma companies. NBE offers high-quality, cost-effective services for discovering and developing new advanced biopharmaceuticals such as Antibody Drug Conjugates (ADC), mRNA and CAR-T.

Large molecule therapeutics or biotherapeutics are more advanced drugs that represent a rapidly growing segment of the therapeutics market, and this move further underlines Aurigene's commitment to serving its global biopharma clients in the areas of these therapeutic technologies.

"This expansion was a logical step to leverage our capabilities further and to meet the global demand of domestic and international pharma companies. We are well-positioned through our integrated expertise and resources to support our clients in the discovery and development of biologics and vaccines in a flexible and fast manner," said Ravi Venkataramanan, CEO of Aurigene.

The expansion complements Aurigene's existing services for small and large molecule drugs from discovery to launch.

About Aurigene Pharmaceutical Services Limited

Aurigene Pharmaceutical Services is a leading contract research, development and manufacturing organization (CDMO). Built on the legacy of accelerating innovation and backed by a vast experience in drug discovery, development and manufacturing our mission is to relentlessly work for the success of our clients and to build long-term relationships through a holistic approach to accelerate the journey of a molecule from the laboratory to market. By providing access to our resources, knowledge and experience, we create success for our clients and, ultimately, patients. We offer integrated and standalone services for discovery chemistry, discovery biology, development and manufacturing services for clinical phase I-III programs, regulatory submission batches and commercial manufacturing. A differentiating factor is the integrated API and formulations service that spans from key starting material, advanced intermediates, APIs to finished products such as oral solids, sterile products, nasal solutions etc. Our development services in India are complemented by cGMP commercial manufacturing facilities in the UK, Mexico, USA and India.



Caption: Inauguration with Dr. Reddy's Co-Chairman and Managing Director, G V Prasad.